Research programme: cancer therapeutics - Arch BioPartners/University of Colorado

Drug Profile

Research programme: cancer therapeutics - Arch BioPartners/University of Colorado

Alternative Names: GH501a

Latest Information Update: 10 Jul 2016

Price : $50

At a glance

  • Originator University of Colorado Foundation
  • Developer Arch Biopartners; University of Colorado Foundation
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 09 Sep 2011 A lead compound, GH 501a, is selected for further development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top